NEW YORK, NY / ACCESS Newswire / September 8, 2025 / Levi & Korsinsky, LLP releases a Podcast regarding Capricor Therapeutics, Inc. (NASDAQ:CAPR) class action securities lawsuit
A Class Action lawsuit was filed on behalf of Capricor Therapeutics, Inc. investors who lost money as a result of alleged securities fraud between October 9, 2024 and July 10, 2025.
Levi & Korsinsky has released a Podcast describing the nature of the action. The podcast for this class action lawsuit can be found here:
According to the complaint, defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.
On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application.
Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025.
If you have any questions about this class action lawsuit or any other sudden or unexpected stock loss, feel free to contact Levi & Korsinsky at (212)-363-7500.
You can also find recent podcasts regarding other class actions lawsuits and topics which are of interest to shareholders that have lost money in the stock market, here:
https://suewallst.podbean.com/
LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
COMTEX_468629700/2457/2025-09-08T07:46:03